ライフサイエンスコーパス: granulocyte count

1 on day 5 at 5 microg/kg/d until recovery of granulocyte count.

2 ly depressed peripheral white blood cell and granulocyte counts.

3 e loci were identified after conditioning on granulocyte counts.

4 severity, worse lung function, and elevated granulocyte counts.

5 ) cyclins (D1, D2, E1, or E2) display normal granulocyte counts.

6 chieved targeted neutropenia (nadir absolute granulocyte count, 100 to 1,000/microL) without any othe

7 MD = 0.57; 95% CI, 0.12 to 1.01), neutrophil granulocyte count (21 studies, SMD = 0.32; 95% CI, 0.11

8 ference [SMD] = 0.35; 95% CI, 0.24 to 0.46), granulocyte count (4 studies, SMD = 0.57; 95% CI, 0.12 t

9 less, creatinine level less than 2.0 mg/dL, granulocyte count (AGC) 1,500/microL or greater, platele

10 h day 19 of each cycle or until the absolute granulocyte count (AGC) was > or = 500/microliter on 2 c

11 The median nadir absolute granulocyte count (AGC) was 1,500/microL.

12 g on day 6 and continuing until the absolute granulocyte count (AGC) was greater than 10,000/microL.

13 creases in the clinical white blood cell and granulocyte count and is a well-documented effect of glu

14 ex (OMI), speed of engraftment (platelet and granulocyte counts), and bilirubin.

15 nucleic acid sequences, bacterial cultures, granulocyte counts, and phlebotomy for both general and

16 nd CD36 receptors, also increased peritoneal granulocyte counts, as well as reduced peritoneal bacter

17 Basal total white blood cell and granulocyte counts did not appreciably differ between PM

18 ntoxication suppressed the increase in blood granulocyte counts following intrapulmonary challenge wi

19 gh-dose CEC, the median time from AuBMT to a granulocyte count > or = 0.5/microL was 11 days (range,

20 ance status of 0 to 2, pretreatment absolute granulocyte count > or = 1,500/microL, and platelet coun

21 i were significantly associated with reduced granulocyte counts in a small independent sample of cloz

22 Doses were modified for granulocyte counts less than 1,800/microL or neurotoxici

23 nts associated with clozapine metabolism and granulocyte counts may form the basis for developing pre

24 The median time to a granulocyte count more than 500/dL was 19 days (range, 1

25 A baseline granulocyte count of more than 1000 cells/microL was pro

26 Overlaying granulocyte counts onto the 10 clusters as metadata furt

27 reatinine concentration (P = 0.008), and low granulocyte count (P = 0.003) as risk factors for infect

28 ession and age, sex, white blood cell count, granulocyte count, the presence of additional cytogeneti

29 wer for genetic discovery by conditioning on granulocyte counts variants.

30 After conditioning on granulocyte counts, we identified two novel loci associa

31 l adverse effects involving the reduction of granulocyte counts with potential life-threatening agran